Scientists hunt for biomarkers to predict immunotherapy success in liver cancer

NCT ID NCT07186010

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is collecting blood and tumor samples from 50 people with advanced liver cancer who are receiving immunotherapy. Researchers will analyze the samples to find genetic and immune system markers that might predict how well the treatment works. The goal is to better understand why some patients respond to immunotherapy and others do not.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors predict which liver cancer patients will benefit most from immunotherapy, leading to more personalized treatment.

What could go wrong

This is an early-stage observational study with only 50 participants, so results may not apply to all patients. It is designed to gather information, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, Song-pa, 05505, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••